{"id":"fluvoxamine-methylphenidate-hydrochloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Decreased appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake at the presynaptic neuron, increasing serotonin availability in synaptic spaces. Methylphenidate is a stimulant that blocks dopamine and norepinephrine reuptake, enhancing attention and executive function. The combination targets complementary neurotransmitter systems to treat conditions with both depressive/anxiety and attentional components.","oneSentence":"This combination uses fluvoxamine to increase serotonin levels in the brain while methylphenidate increases dopamine and norepinephrine, together addressing both mood and attention symptoms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:30:45.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Depression with comorbid attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Obsessive-compulsive disorder with attentional symptoms"}]},"trialDetails":[{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT02194075","phase":"PHASE4","title":"Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2013-10","conditions":"Obsessive Compulsive Disorder","enrollment":60},{"nctId":"NCT00012584","phase":"NA","title":"Treatment of Youth With ADHD and Anxiety","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2000-11","conditions":"Attention Deficit Hyperactivity Disorder, Anxiety, Separation, Social Phobia","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fluvoxamine+Methylphenidate hydrochloride","genericName":"Fluvoxamine+Methylphenidate hydrochloride","companyName":"Guangdong Provincial People's Hospital","companyId":"guangdong-provincial-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses fluvoxamine to increase serotonin levels in the brain while methylphenidate increases dopamine and norepinephrine, together addressing both mood and attention symptoms. Used for Depression with comorbid attention-deficit/hyperactivity disorder (ADHD), Obsessive-compulsive disorder with attentional symptoms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}